1. Home
  2. KPTI vs SNAL Comparison

KPTI vs SNAL Comparison

Compare KPTI & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • SNAL
  • Stock Information
  • Founded
  • KPTI 2008
  • SNAL 2000
  • Country
  • KPTI United States
  • SNAL United States
  • Employees
  • KPTI N/A
  • SNAL N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • SNAL Computer Software: Prepackaged Software
  • Sector
  • KPTI Health Care
  • SNAL Technology
  • Exchange
  • KPTI Nasdaq
  • SNAL Nasdaq
  • Market Cap
  • KPTI 81.1M
  • SNAL 92.8M
  • IPO Year
  • KPTI 2013
  • SNAL 2022
  • Fundamental
  • Price
  • KPTI $0.62
  • SNAL $2.72
  • Analyst Decision
  • KPTI Strong Buy
  • SNAL
  • Analyst Count
  • KPTI 4
  • SNAL 0
  • Target Price
  • KPTI $5.00
  • SNAL N/A
  • AVG Volume (30 Days)
  • KPTI 751.1K
  • SNAL 146.8K
  • Earning Date
  • KPTI 02-19-2025
  • SNAL 03-31-2025
  • Dividend Yield
  • KPTI N/A
  • SNAL N/A
  • EPS Growth
  • KPTI N/A
  • SNAL N/A
  • EPS
  • KPTI N/A
  • SNAL 0.08
  • Revenue
  • KPTI $148,442,000.00
  • SNAL $86,822,973.00
  • Revenue This Year
  • KPTI $4.47
  • SNAL $39.43
  • Revenue Next Year
  • KPTI $7.35
  • SNAL $26.12
  • P/E Ratio
  • KPTI N/A
  • SNAL $35.99
  • Revenue Growth
  • KPTI 1.77
  • SNAL 82.23
  • 52 Week Low
  • KPTI $0.58
  • SNAL $0.52
  • 52 Week High
  • KPTI $1.70
  • SNAL $3.42
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 43.29
  • SNAL 57.64
  • Support Level
  • KPTI $0.58
  • SNAL $2.61
  • Resistance Level
  • KPTI $0.67
  • SNAL $3.42
  • Average True Range (ATR)
  • KPTI 0.05
  • SNAL 0.34
  • MACD
  • KPTI -0.00
  • SNAL 0.03
  • Stochastic Oscillator
  • KPTI 31.02
  • SNAL 60.92

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About SNAL Snail Inc.

Snail Inc is a global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.

Share on Social Networks: